Meta-Analysis: Chronic Gastrointestinal Symptoms and Comorbidities in Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders
Abstract
Background: Patients with Ehlers-Danlos syndrome (EDS)/hypermobility spectrum disorders (HSD) report higher rates of chronic gastrointestinal (GI) symptoms, disorders of gut-brain interaction (DGBI), and extraintestinal comorbidities.
Aims: We conducted a systematic review and meta-analysis to assess the prevalence of chronic GI symptoms and comorbid conditions in hEDS/HSD.
Methods: Electronic databases were searched until December 2025 for studies reporting on chronic GI symptoms in hEDS/HSD patients. Pooled prevalence rates, odds ratios (ORs), and 95% confidence intervals (CIs) were calculated using the random effects model.
Results: The final dataset of 19 studies included 17,455 hEDS/HSD patients and 1,677,465 controls. The odds of chronic GI symptoms were higher in patients with hEDS/HSD compared to controls (OR 4.29, 95% CI 3.1-6.0). 65.3% (95% CI 51.4-77.0) of hEDS/HSD patients reported at least one chronic GI symptom, with heartburn being the most common (34.7%, 95% CI 28.3-41.7). The prevalence of DGBI in hEDS/HSD patients was 44.2% (95% CI 23.9-66.6), with functional dysphagia the most common DGBI at 34.2% (95% CI 25.7-43.8). Gastroesophageal reflux disease was reported in 41.3% (95% CI 27.2-57.0). In hEDS/HSD patients, the most common extraintestinal comorbidity was chronic fatigue (49%, 95% CI 34.6-63.6), followed by migraine (38.2%, 95% CI 19.9-60.5), orthostatic intolerance (OI) (35.9%, 95% CI 26.6-46.4), fibromyalgia (27.9%, 95% CI 16.0-44.0) and postural…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.